Application of local ablative therapies for hepatocellular carcinoma

Zhu XiaoLi; Shen Jian

doi:10.3969/j.issn.1001-5256.2016.01.008

Volume 32 Issue 1

Jan. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(1): 56-61

PDF( 1512 KB)

Application of local ablative therapies for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2016.01.008

Department of Interventional Radiology,The First Affiliated Hospital of Soochow University

Research funding:

Received Date: 2015-11-03
Published Date: 2016-01-20

Abstract

Abstract

Hepatocellular carcinoma( HCC) is a common malignant tumor in the world,and surgical resection and liver transplantation are two radical treatment modalities,but only 10%- 20% of all patients can receive such treatments. In recent years,local therapies including radiofrequency ablation,microwave ablation,cryoablation,and the irreversible electroporation ablation which appeared recently have gradually become the alternative therapies for the patients who are unable to undergo surgery. In addition to local tumor growth control and improvement in survival outcomes,the ablation technology also helps to downgrade tumor for secondary resection. This article focuses on the research progress in radiofrequency ablation alone and in combination with other therapies in the treatment of HCC,compares radiofrequency ablation with other local ablative therapies,and briefly introduces the application of intelligent navigation technology in adjuvant ablation.With the development of medical imaging and progress in related fields,the ablation technology will be widely applied in clinical practice in the future.
- carcinoma,hepatocellular,
- local ablation,
- therapy

FullText(HTML)

References(62)

References

[1]LOZANO R,NAGHAVI M,FOREMAN K,et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J].Lancet,2012,380(9859):2095-2128.

[2]SHIINA S.Image-guided percutaneous ablation therapies for hepatocellular carcinoma[J].J Gastroenterol,2009,44(Suppl 19):122-131.

[3]ROSSI S,di STASI M,BUSCARINI E,et al.Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer[J].AJR Am J Roentgenol,1996,167(3):759-768.

[4] POULOU LS,BOTSA E,THANOU I,et al.Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma[J].World J Hepatol,2015,7(8):1054-1063.

[5]IKEDA K,OSAKI Y,NAKANISHI H,et al.Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma[J].Oncology,2014,87(Suppl 1):73-77.

[6]ZHOU Y,ZHAO Y,LI B,et al.Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma[J].BMC Gastroenterol,2010,10:78.

[7]XU Q,KOBAYASHI S,YE X,et al.Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma:a meta-analysis of 16,103 patients[J].Sci Rep,2014,4:7252.

[8]CUCCHETTI A,PISCAGLIA F,CESCON M,et al.Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma[J].World J Gastroenterol,2013,19(26):4106-4018.

[9]MIURA JT,JOHNSTON FM,TSAI S,et al.Surgical resection versus ablation for hepatocellular carcinoma≤3 cm:a populationbased analysis[J].HPB(Oxford),2015,17(10):896-901.

[10]JIANG L,YAN L,WEN T,et al.Comparison of outcomes of hepatic resection and radiofrequency ablation for hepatocellular carcinoma patients with multifocal tumors meeting the barcelona-clinic liver cancer stage a classification[J].J Am Coll Surg,2015,221(5):951-961.

[11]XIE X,JIANG C,PENG Z,et al.Local recurrence after radiofrequency ablation of hepatocellular carcinoma:treatment choice and outcome[J].J Gastrointest Surg,2015,19(8):1466-1475.

[12]CHOI D,LIM HK,RHIM H,et al.Percutaneous radiofre-quency ablation for recurrent hepatocellular carcinoma after hepatectomy:long-term results and prognostic factors[J].Ann Surg Oncol,2007,14(8):2319-2329.

[13]CHAN AC,POON RT,CHEUNG TT,et al.Survival analysisof re-resection versus radiofrequency ablation for intrahepatic recurrence afterhepatectomy for hepatocellular carcinoma[J].World J Surg,2012,36(1):151-156.

[14]LEE DH,LEE JM,LEE JY,et al.Radiofrequency ablationfor intrahepatic recurrent hepatocellular carcinoma:long-term results andprognostic factors in 168 patients with cirrhosis[J].Cardiovasc Intervent Radiol,2014,37(3):705-715.

[15]FUKUHARA T,AIKATA H,HYOGO H,et al.Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment:comparison with primary cases[J].Eur J Radiol,2015,84(8):1540-1545.

[16]ITAMOTO T,NAKAHARA H,AMANO H,et al.Repeat hepatectomy for recurrent hepatocellular carcinoma[J].Surgery,2007,141(5):589-597.

[17]WU CC,CHENG SB,YEH DC,et al.Second and third hepatectomies forrecurrent hepatocellular carcinoma are justified[J].Br J Surg,2009,96(9):1049-1057.

[18]NEELEMAN N,ANDERSSON R.Repeated liver resection for recurrent liver cancer[J].Br J Surg,1996,83(7):893-901.

[19]FABER W,SEEHOFER D,NEUHAUS P,et al.Repeated liver resection for recurrent hepatocellular carcinoma[J].J Gastroenterol Hepatol,2011,26(7):1189-1194.

[20]HANAZAKI K,KAJIKAWA S,SHIMOZAWA N,et al.Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma[J].J Am Coll Surg,2000,191(4):381-388.

[21]SHIMADA M,TAKENAKA K,GION T,et al.Prognosis of recurrent hepatocellular carcinoma:a 10-year surgical experience in Japan[J].Gastroenterology,1996,111(3):720-726.

[22]SONG KD,LIM HK,RHIM H,et al.Repeated hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after hepatic resection:a propensity score matching study[J].Radiology,2015,275(2):599-608.

[23]CAI H,KONG W,ZHOU T,et al.Radiofrequency ablation versus reresection in treating recurrent hepatocellular carcinoma[J].Medicine(Baltimore),2014,93(22):e122.

[24]INOUE T,MINAMI Y,CHUNG H,et al.Radiofrequency ablation for hepatocellular carcinoma:assistant techniques for difficult cases[J].Oncology,2010,78(Suppl 1):94-101.

[25]TATEISHI R,SHIINA S,TERATANI T,et al.Percutaneous radiofrequency ablation for hepatocellular carcinoma.An analysis of1000 cases[J].Cancer,2005,103(6):1201-1209.

[26]CHOPRA S,DODD GD,CHANIN MP,et al.Radiofrequency ablation of hepatic tumors adjacent to the gallbladder:feasibility and safety[J].AJR Am J Roentgenol,2003,180(3):697-701.

[27]CHOI D,LIM HK,KIM MJ,et al.Therapeutic efficacy and safety of percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the gastrointestinal tract[J].AJR Am J Roentgenol,2004,183(5):1417-1424.

[28]KODA M,UEKI M,MAEDA Y,et al.Percutaneous sonographically guided radiofrequency ablation with artificial pleural effusion for hepatocellular carcinoma located under the diaphragm[J].AJR Am J Roentgenol,2004,183(3):583-588.

[29]YANG W,YAN K,WU G,et al.Radiofrequency ablation of hepatocellular carcinoma in difficult locations:strategies and long-term outcomes[J].World J Gastroenterol,2015,21(5):1554-1566.

[30] LIVRAGHI T,SOLBIATI L,MELONI MF,et al.Treatment of focal liver tumors with percutaneous radio-frequency ablation:complications encountered in a multicenter study[J].Radiology,2003,226(2):441-451.

[31]TERATANI T,YOSHIDA H,SHIINA S,et al.Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations[J].Hepatology,2006,43(5):1101-1108.

[32]MULIER S,MULIER P,NI Y,et al.Complications of radiofrequency coagulation of liver tumours[J].Br J Surg,2002,89(10):1206-1222.

[33] RHIM H,YOON KH,LEE JM,et al.Major complications after radio-frequency thermal ablation of hepatic tumors:spectrum of imaging findings[J].Radiographics,2003,23(1):123-134.

[34]CHENG AL,KANG YK,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised,double-blind,placebocontrolled trial[J].Lancet Oncol,2009,10(1):25-34.

[35] LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.

[36]LU LC,CHENG AL,POON RTP.Recent advances in the prevention of hepatocellular carcinoma recurrence[J].Semin Liver Dis,2014,34(4):427-434.

[37]FENG X,XU R,DU X,et al.Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma:a multicenter retrospective cohort study[J].Am J Gastroenterol,2014,109(12):1891-1899.

[38]BRUIX J,TAKAYAMA T,MAZZAFERRO V,et al.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation(STORM):a phase 3,randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2015,16(13):1344-1354.

[39]BENSON AB 3rd,ABRAMS TA,BEN-JOSEF E,et al.NCCN clinical practice guidelines in oncology:hepatobiliary cancers[J].J Natl Compr Cancer Netw,2009,7(4):350-391.

[40]OMATA M,LESMANA LA,TATEISHI R,et al.Asian Pacific Association for the Study of the Liverconsensus recommendations on hepatocellular carcinoma[J].Hepatol Int,2010,4(2):439-474.

[41]LLOVET JM,REAL MI,MONTAAX,et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet,2002,359(9319):1734-1739.

[42]LO CM,NGAN H,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171.

[43]LOVET JM,BRUIX J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival[J].Hepatology,2003,37(2):429-442.

[44]YIN X,ZHANG L,WANG YH,et al.Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate(BCLC B)hepatocellular carcinoma[J].BMC Cancer,2014,14:849.

[45]IEZZI R,POMPILI M,la TORRE MF,et al.Radiofrequency ablation plus drug-eluting beads transcatheterarterial chemoembolization for the treatment of single largehepatocellular carcinoma[J].Dig Liver Dis,2015,47(3):242-248.

[46]WANG C,LU Y,CHEN Y,et al.Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argonhelium cryoablation:a prospective study[J].Clin Exp Metastasis,2009,26(7):839-848.

[47]YANG Y,WANG C,LU Y,et al.Outcomes of ultrasoundguided percutaneous argon-helium cryoablation of hepatocellular carcinoma[J].J Hepatobil Pancreat Sci,2012,19(6):674-684.

[48]WANG C,WANG H,YANG W,et al.Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma[J].Hepatology,2015,61(5):1579-1590.

[49]LIANG P,YU J,LU MD,et al.Practice guidelines for ultrasoundguided percutaneous microwave ablation for hepatic malignancy[J].World J Gastroenterol,2013,19(33):5430-5438.

[50]LIANG P,WANG Y,YU X,et al.Malignant liver tumors:treatment with percutaneous microwave ablation-complications among cohort of 1136 patients[J].Radiology,2009,251(13):933-940.

[51]LIANG P,YU J,YU XL,et al.Percutaneous cooled-tip microwave ablation under ultrasound guidance for primary liver cancer:a multicentre analysis of 1363 treatment-naive lesions in 1007 patients in China[J].Gut,2012,61(7):1100-1101.

[52]POULOU LS,BOTSA E,THANOU I,et al.Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma[J].World J Hepatol,2015,7(8):1054-1063.

[53]SCHEFFER HJ,NIELSEN K,de JONG MC,et al.Irreversible electroporation for nonthermal tumor ablation in the clinical setting:a systematic review of safety and efficacy[J].J Vasc Interv Radiol,2014,25(7):997-1011.

[54]NARAYANAN G,FROUD T,SUTHAR R,et al.Irreversible electroporation of hepatic malignancy[J].Semin Intervent Radiol,2013,30(1):67-73.

[55]WU J,CHEN P,XIE YG,et al.Comparison of the effectiveness and safety of ultrasound-and CT-guided percutaneous radiofrequency ablation of non-operation hepatocellular carcinoma[J].Pathol Oncol Res,2015,21(3):637-642.

[56]KIM J,YOON CJ,SEONG NJ,et al.Fluoroscopy-guided radiofrequency ablation for small hepatocellular carcinoma:a retrospective comparison with ultrasound-guided ablation[J].Clin Radiol,2015,70(9):1009-1015.

[57]CHAN AK,HEGARTY C,KLASS D,et al.The role of contrastenhanced ultrasound in guiding radiofrequency ablation of hepatocellular carcinoma:a retrospective study[J].Can Assoc Radiol J,2015,66(2):171-178.

[58]TOSHIKUNI N,TSUTSUMI M,TAKUMA Y,et al.Real-time image fusion for successful percutaneous radiofrequency ablation of hepatocellular carcinoma[J].J Ultrasound Med,2014,33(11):2005-2010.

[59]LEE CH,CHEN WT,LIN CC,et al.Radiofrequency ablation assisted by real-time virtual sonography for hepatocellular carcinoma inconspicuous under sonography and high-risk locations[J].Kaohsiung J Med Sci,2015,31(8):413-419.

[60]LIN ZY,SONG QQ,CHEN J,et al.Local curative effect of MRIguided radiofrequency ablation on small hepatocellular carcinoma[J].Tumour Biol,2015,36(3):2105-2110.

[61]KOETHE Y,XU S,VELUSAMY G,et al.Accuracy and efficacy of percutaneous biopsy and ablation using robotic assistance under computed tomography guidance:a phantom study[J].Eur Radiol,2014,24(3):723-730.

[62]ABDULLAH BJ,YEONG CH,GOH KL,et al.Robot-assisted radiofrequency ablation of primary and secondary liver tumours:early experience[J].Eur Radiol,2014,24(1):79-85.

Relative Articles

[1]	Yu SUN, Honghai ZHANG, Jiang LONG, Shoupeng SHENG, Jiasheng ZHENG, Yonghong ZHANG. Influence of the interval between transcatheter arterial embolization and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(10): 2286-2289. doi: 10.3969/j.issn.1001-5256.2022.10.016
[2]	Lu Jian, Zhu HaiDong, Teng GaoJun, Wang Zhi. Role of interventional therapy in the downstaging of advanced liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(2): 272-276. doi: 10.3969/j.issn.1001-5256.2020.02.006
[3]	Tang JinQuan, He Pan, Su Song, Luo Bin, Fang Cheng, Li Bo, Xia XianMing, Li YuWei. Short-and long-term effects of radiofrequency ablation versus minimally invasive hepatectomy in treatment of small hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 358-362. doi: 10.3969/j.issn.1001-5256.2020.02.025
[4]	Xiang Jiao, Jia XiaoDong, Lu ShanShan, Wu DaWei, Zhang Ting, Dong JinKe, Huang JiaGan, Li YinYin, Yang Bin, Xu Yong, Dong Zheng, Lu Ying, Zeng Zhen, Lu YinYing. Effect of cryoablation versus microwave ablation on clinical indices and cytokines in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(8): 1728-1733. doi: 10.3969/j.issn.1001-5256.2019.08.016
[5]	Liu BoZhi, Yuan ZhuHui, Li Wei. A case of large hepatocellular carcinoma treated by transcatheter arterial chemoembolization combined with radiofrequency ablation[J]. Journal of Clinical Hepatology, 2018, 34(7): 1520-1522. doi: 10.3969/j.issn.1001-5256.2018.07.031
[7]	Huang YongJie, Wu DeQuan, Yuan JunHui. Current status of treatment of primary hepatocellular carcinoma in the elderly population[J]. Journal of Clinical Hepatology, 2018, 34(6): 1313-1317. doi: 10.3969/j.issn.1001-5256.2018.06.039
[8]	Yao ChangYu, Du YingRui, Ke Shan, Gao Jun, Sun WenBing. Current status of non-surgical local therapies for hepatocellular carcinoma originating from the caudate lobe and related research advances[J]. Journal of Clinical Hepatology, 2018, 34(1): 195-198. doi: 10.3969/j.issn.1001-5256.2018.01.043
[9]	Gao Si, Zhao XiangXuan, Lu ZaiMing. Role of cell apoptosis regulated by P53 in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(7): 1373-1376. doi: 10.3969/j.issn.1001-5256.2017.07.038
[10]	Dong Jing, Jiang JiaJi. Antiviral therapy for hepatitis virus-related hepatocellular carcinoma:current status and challenges[J]. Journal of Clinical Hepatology, 2017, 33(7): 1270-1273. doi: 10.3969/j.issn.1001-5256.2017.07.013
[11]	Wang Peng, Ren WeiDong. Mechanism of radiofrequency ablation in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(2): 359-363. doi: 10.3969/j.issn.1001-5256.2017.02.035
[12]	Li Jing, Qi XingShun, Han Tao, Li HongYu. An excerpt of AASLD guidelines for the treatment of hepatocellular carcinoma (2016)[J]. Journal of Clinical Hepatology, 2017, 33(4): 621-622. doi: 10.3969/j.issn.1001-5256.2017.04.003
[13]	Chen WeiBo, Cai HuiHua, Yang Yue, Chen XueMin, Jiang Yong, Sun DongLin. Research advances in regorafenib in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(12): 2425-2428. doi: 10.3969/j.issn.1001-5256.2017.12.039
[14]	Luo DanDong, Qiao AnYi. Research advances in radiofrequency ablation in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(7): 1358-1361. doi: 10.3969/j.issn.1001-5256.2017.07.034
[15]	Yang ZhenYu, Du XiLin, Yang Tao, Tan Kai, He XiaoJun, Chen An. Basic research and therapeutic strategies for multinodular hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(6): 1212-1215. doi: 10.3969/j.issn.1001-5256.2016.06.046
[16]	Ma YiYun, Jiang Hua, Zhang HongHeng. Clinical effect of laparoscopic versus open liver resection in treatment of patients with hepatocellular carcinoma complicated by liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(10): 1916-1919. doi: 10.3969/j.issn.1001-5256.2016.10.018
[17]	Wang HuaMing. The interventional treatment for hepatocellular carcinoma originating from the caudate lobe[J]. Journal of Clinical Hepatology, 2016, 32(1): 68-71. doi: 10.3969/j.issn.1001-5256.2016.01.010
[18]	Jia WeiDong, Liu WenBin. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Journal of Clinical Hepatology, 2015, 31(6): 859-862. doi: 10.3969/j.issn.1001-5256.2015.06.009
[19]	Chen Peng, Li Fei. New progress in treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Journal of Clinical Hepatology, 2015, 31(6): 974-976. doi: 10.3969/j.issn.1001-5256.2015.06.036
[20]	Sun JingJuan, Zhao HengJun, Li Wei, Miao FengHua, Wang NanYa. Clinical study of radiofrequency ablation therapy in combination with sorafenib for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2011, 27(10): 1093-1095+1098.

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	唐澄海. DAB2在肝癌中表达及临床意义的研究. 世界复合医学. 2020(11): 19-22+34 .
2.	刘曙民，孙邱，张美菊. 微波凝固坏死疗法联合腹腔镜脾切除术治疗原发性肝癌合并脾功能亢进的效果观察. 临床肝胆病杂志. 2018(01): 142-146 . 本站查看
3.	杨雅阁，李鸿彬，张孟徐，张炳勇. 肝细胞癌脑转移相关预后因素及临床结局分析. 医药论坛杂志. 2018(09): 67-69 .
4.	吴绍锋，李柳生，黄智勇，罗文高，魏达友. 超声引导经皮微波消融治疗肝转移癌患者对临床疗效及局部复发率分析. 现代医用影像学. 2018(08): 2811-2812+2815 .
5.	曹焱，姜峰，张超，潘慧丽. 肝动脉栓塞化疗联合CT引导精准微波消融治疗原发性肝癌患者疗效及对外周血T淋巴细胞亚群的影响. 实用肝脏病杂志. 2017(04): 468-471 .
6.	罗丹东，乔安意. 射频消融治疗肝细胞癌的研究进展. 临床肝胆病杂志. 2017(07): 1358-1361 . 本站查看
7.	李明，宋万立，陈敬生，金军. 康艾注射液对肝癌患者经皮射频消融术后生活质量的影响. 现代肿瘤医学. 2016(18): 2926-2930 .
8.	徐娟，赵晔，付晓丹，崔永慧，顾丽婕，赵静，葛华. 超声引导下经皮微波消融与射频消融治疗原发性肝癌的临床疗效对比分析. 中国医学装备. 2016(12): 55-59 .

Other cited types(5)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3144) PDF downloads(505)

Application of local ablative therapies for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2016.01.008